Disclosed herein are methods of producing a cartilaginous implant by producing a polymer scaffold composition by electrospinning a polymer solution onto a collector in order to obtain polymer fibers; crosslinking the polymer fibers; and adding a plurality of cells to the polymer scaffold composition, wherein the plurality of cells comprises cartilaginous cells to form a cartilaginous implant.

Disclosed herein are compounds of formula (I)

##STR00001##

and therapeutic methods of treatment with compounds of formula (I), wherein L.sup.1, L.sup.2, L.sup.4, R.sup.1, R.sup.4, R.sup.5, R.sup.6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Disclosed herein are compounds of formula (I)

##STR00001##

and therapeutic methods of treatment with compounds of formula (I), wherein L.sup.1, L.sup.2, L.sup.4, R.sup.1, R.sup.4, R.sup.5, R.sup.6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Medical stent designs are disclosed. An example stent includes a tubular scaffold having a proximal end and a distal end. The tubular scaffold includes a first filament extending between the proximal end and the distal end, the first filament including a first biodegradable region positioned adjacent to a second biodegradable region. Further, the first biodegradable region includes a first biodegradable material, the first biodegradable material having a first rate of degradation. The second biodegradable region includes a second biodegradable material, the second biodegradable material having a second rate of degradation, wherein the first rate of degradation is different from the second rate of degradation.

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

The present solution can temporarily impart the handling characteristics of corneal stroma to the otherwise very thin, flimsy, coiling, and fragile Descemet membrane endothelial keratoplasty (DMEK) tissue during its insertion into the anterior chamber and positioning in apposition against the cornea of the recipient eye. The device of the present solution can be configured in a number of ways. In a first configuration, a scaffold can be coupled with the endothelial side of the DMEK graft. In a second configuration, the scaffold can be coupled with the stromal side of the DMEK graft. In a third configuration, one or more scaffolds can be coupled with both the endothelial and stromal side of the DMEK graft.

The present solution can temporarily impart the handling characteristics of corneal stroma to the otherwise very thin, flimsy, coiling, and fragile Descemet membrane endothelial keratoplasty (DMEK) tissue during its insertion into the anterior chamber and positioning in apposition against the cornea of the recipient eye. The device of the present solution can be configured in a number of ways. In a first configuration, a scaffold can be coupled with the endothelial side of the DMEK graft. In a second configuration, the scaffold can be coupled with the stromal side of the DMEK graft. In a third configuration, one or more scaffolds can be coupled with both the endothelial and stromal side of the DMEK graft.

Provided is a medical calcium carbonate composition that highly satisfies 1) tissue affinity, 2) in vivo resorbability, 3) reactivity, and 4) mechanical strength required for medical materials to be implanted in vivo, a medical calcium phosphate composition, a medical carbonate apatite composition, a medical calcium hydroxide porous structure, a medical calcium sulfate setting granules, and a bone defect regeneration kit related to the medical calcium carbonate composition, and methods for producing these. The medical composition calcium carbonate that highly satisfies the above described elements, and related medical compositions can be produced by controlling the polymorph or structure of calcium carbonate.

Medical stent designs are disclosed. An example stent includes a tubular scaffold having a proximal end and a distal end. The tubular scaffold includes a first filament extending between the proximal end and the distal end, the first filament including a first biodegradable region positioned adjacent to a second biodegradable region. Further, the first biodegradable region includes a first biodegradable material, the first biodegradable material having a first rate of degradation. The second biodegradable region includes a second biodegradable material, the second biodegradable material having a second rate of degradation, wherein the first rate of degradation is different from the second rate of degradation.